Thursday 16 October, 2025
Introduction: Retrospective studies using clinical data from cancer patients usually are analysed using Cox Proportional Hazards CPH. [1] This approach has…
Read morePoster: Drug/Disease Modelling - Oncology
A model based approach to infer overall survival (OS) in hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (HR+/HER2- mBC)
Thursday 16 October, 2025
Introduction: Assessment of benefit in clinical trials of systemic therapy for HR+/HER2- mBC is commonly performed by using progression free…
Read morePharmacometric analysis to justify a higher recommended dose for trastuzumab deruxtecan in the treatment of subjects with metastatic gastric cancer versus breast cancer
Thursday 16 October, 2025
Introduction: Trastuzumab deruxtecan (T-DXd) is a newer antibody-drug conjugate consisting of an anti-HER2 antibody linked to a topoisomerase I inhibitor….
Read moreImproving the tolerability of osimertinib by identifying its toxic limit
Thursday 16 October, 2025
Objectives: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). Nonetheless,…
Read moreModelling fatigue events in prostate cancer patients on radiotherapy
Thursday 16 October, 2025
Introduction: The second most common form of cancer in the male population is prostate cancer. Therapeutic options include radical prostatectomy, different…
Read morePopulation pharmacokinetics of abiraterone in patients with metastatic castration resistant prostate cancer
Thursday 16 October, 2025
Introduction/Objectives: Abiraterone acetate is approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) [1,2]. After oral administration, abiraterone…
Read moreOptimizing the value of preclinical data for the design of first-in-human clinical studies with oral cabazitaxel through population pharmacokinetic modelling
Thursday 16 October, 2025
Introduction Cabazitaxel is currently approved as an intravenous (IV) formulation for the second line treatment of hormone refractory prostate cancer…
Read morePharmacokinetic and pharmacodynamic modelling of different oral paclitaxel formulations co-administered with ritonavir.
Thursday 16 October, 2025
Introduction: The oral administration of the widely used anticancer agent paclitaxel has several benefits compared to the conventional intravenous (IV)…
Read moreCosts of pemetrexed-associated neutropenia and the budget impact of pemetrexed dose individualization
Thursday 16 October, 2025
Objectives: Pemetrexed is an antifolate used in the treatment of lung cancer, in combination with other agents or as monotherapy….
Read moreCharacterizing the interplay between biological factors and cell growth in unperturbed tumor growth dynamics
Thursday 16 October, 2025
Objectives: Mathematical modeling of unperturbed and perturbed tumor growth dynamics (TGD) in preclinical experiments provides an opportunity to establish translational…
Read more